# US 2018/0022828 A1 · Chimeric antigen receptors with an optimized hinge region

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022828 A1
- Document ID: US20180022828A1
- Status: Published application
- Kind: A1
- Application number: 15/726,943
- Filed: 2017-10-06
- Published: 2018-01-25
- Earliest claimed: 2010-09-08
- Assignees: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus
- Applicants: Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus
- Inventors: Kurt SCHÖNFELD; Christiane SCHÖNFELD; Winfried WELS
- Web page: https://patentgrep.com/patent/US20180022828A1

## CPC

- C07K 16/46: Hybrid immunoglobulins (hybrids of an immunoglobulin with a peptide not being an immunoglobulin C07K19/00)
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 16/32: against translation products of oncogenes
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/626: Diabody or triabody
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to multi-functional proteins which comprise (i) a signal peptide, (ii) a target specific recognition domain, (iii) a linker region, connecting domain (ii) and domain (iv) which comprises a specific modified hinge region of the human CD8 alpha-chain, and (iv) an effector domain. The present invention furthermore relates to nucleic acids encoding the proteins, expression constructs for expressing the protein in a host cell and host cells. The proteins of the invention are chimeric antigen receptors with an optimized linker or hinge region that are suitable for generating target-specific effector cells, for use as a medicament, in particular in the treatment of cancer and in adoptive, target-cell specific immunotherapy.

## Claims

### Claim 1

A protein comprising
(i) a signal peptide;
(ii) a target specific recognition domain;
(iii) a linker region, connecting domain (ii) and domain (iv),
wherein the linker region does not contain cysteine residue(s) and is selected from any of the following:
the amino acid sequence of SEQ ID NO. 2,
an amino acid sequence with at least 95% sequence identity to SEQ ID NO. 2 under the proviso that amino acid residue 48 is not a cysteine and is a serine, and
an amino acid sequence that differs in one, two or three amino acid residues from the amino acid sequence of SEQ ID NO. 2 under the proviso that amino acid residue 48 is not a cysteine and is a serine; and
(v) an effector domain comprising a transmembrane region and one or more intracellular signaling domains,
wherein the effector domain triggers lymphocyte activation.

### Claim 2 (depends on 1)

The protein of claim 1, wherein the target is a cell or a virus and wherein the target specific recognition domain (ii) binds an antigen, receptor, peptide ligand or protein ligand of the target.

### Claim 3 (depends on 1)

The protein of claim 1, wherein the target specific recognition domain (ii) comprises
an antigen binding domain derived from an antibody against an antigen of the target, or
a peptide binding an antigen of the target, or
a peptide or protein binding an antibody that binds an antigen of the target, or
a peptide or protein ligand binding a receptor on the target, or
a domain derived from a receptor binding a peptide or protein ligand on the target.

### Claim 4 (depends on 3)

The protein of claim 3, wherein the peptide or protein ligand is a growth factor, cytokine, or hormone, and wherein the receptor is a growth factor receptor, cytokine receptor or hormone receptor.

### Claim 5 (depends on 1)

The protein of claim 1, wherein the antigen of the target is a tumor-associated surface antigen, a lineage-specific or tissue-specific surface antigen or a virus-specific surface antigen.

### Claim 6 (depends on 1)

The protein of claim 1, wherein the antigen binding domain of domain (ii) is derived from an antibody or an antibody fragment.

### Claim 7 (depends on 6)

The protein of claim 6, wherein the antibody fragment is a single chain Fv (scFv) fragment, Fab fragment, a diabody, a variable domain of the antibody heavy chain or antibody light chain.

### Claim 8 (depends on 1)

The protein of claim 1, wherein the effector domain (iv) comprises:
(a) the zeta-chain of the human CD3 complex of the T-cell receptor or a fragment or a functional equivalent thereof; or
(b) a fusion of a fragment of the human costimulatory CD28 receptor fused to a fragment of the zeta-chain of the human CD3 complex of the T-cell receptor.

### Claim 9 (depends on 8)

The protein of claim 8, wherein the effector domain (iv) comprises a fusion of the transmembrane and intracellular domain of human CD28 with the intracellular domain of human CD3 zeta chain.

### Claim 10 (depends on 8)

The protein of claim 8, wherein the effector domain (iv) comprises the amino acid sequence of SEQ ID NO: 3 or SEQ ID NO: 5.

### Claim 11 (depends on 1)

The protein of claim 1 comprising the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 7, or an amino acid sequence that has at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 7 under the proviso that amino acid residue no. 308 is not a cysteine and is a serine.

### Claim 12 (depends on 1)

A nucleic acid encoding the protein of claim 1.

### Claim 13 (depends on 12)

The nucleic acid of claim 12, comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO: 2 or comprising a nucleic acid sequence of SEQ ID NO: 8 or their complementary sequences or sequences that have at least 95% sequence identity.

### Claim 14 (depends on 12)

The nucleic acid of claim 12, comprising a nucleic acid encoding the amino acid sequence of SEQ ID NOs: 3 or 5 or encoding amino acid residues 29-163 of SEQ ID NO: 3 or comprising the nucleic acid sequence of SEQ ID NOs: 9 or 10 or their complementary sequences or sequences that have at least 95% sequence identity.

### Claim 15 (depends on 12)

The nucleic acid of claim 12, comprising a nucleic acid encoding the amino acid sequence of SEQ ID NOs: 6 or 7 or the nucleic acid sequence of SEQ ID NOs: 11 or 12, or their complementary sequences or sequences that have at least 95% sequence identity.

### Claim 16 (depends on 12)

An expression construct comprising a nucleic acid sequence of claim 12, and promoter and terminator sequences.

### Claim 17 (depends on 1)

A host cell expressing a protein of claim 1, wherein the host cell is an effector cell of the immune system.

### Claim 18 (depends on 17)

The host cell of claim 17, wherein the cell is a natural killer (NK) cell, natural killer T (NKT) cell, or a lymphocyte preparation containing a NK cell or a NKT cell.

### Claim 19 (depends on 1)

A method for generating a target-specific effecter cell wherein said method comprises contacting an effector cell with a protein of claim 1.

### Claim 20 (depends on 1)

A method for the treatment of cancer or for adoptive, target-cell specific immunotherapy, wherein said method comprises the use of the protein of claim 1.
